Sanofi says it's back to the drawing board on mRNA flu vaccines

Sanofi, one of the top global vaccine makers, has stated that the current mRNA technology used in COVID-19 vaccines is not effective against influenza. The company is working on a next-generation flu shot based on mRNA, which showed a strong immune response against A strains but not against less prevalent B strains. Sanofi aims to upgrade the technology to improve the immune response against B strains and enhance the durability of the vaccine at normal fridge temperatures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DvK30Bp
via IFTTT